Figures & data
Table 1 Baseline demographic and clinical characteristics from claims
Table 2 Baseline clinical characteristics from medical records
Figure 2 COPD exacerbations during the 12-month pre- and postindex periods.
Abbreviation: FEV1, forced expiratory volume in 1 second.
![Figure 2 COPD exacerbations during the 12-month pre- and postindex periods.](/cms/asset/78c8d33f-167a-42e6-b776-c73c467e3e18/dcop_a_108967_f0002_c.jpg)
Table 3 Baseline all-cause and COPD-related health care resource utilization and costs
Table 4 12-month postindex all-cause and COPD-related health care resource utilization and costs
Figure 3 Factors associated with COPD exacerbations within the 12-month postindex period.
Abbreviations: FEV1, forced expiratory volume in 1 second; PCP, primary care physician; ICS, inhaled corticosteroids; LABA, long-acting β-agonist; LAMA, long-acting muscarinic agent; SAMA, short-acting muscarinic antagonist; SABA, short-acting (inhaled) β2-adrenergic agonist; PDE4 inhibitors, phosphodiesterase-4 inhibitors.
![Figure 3 Factors associated with COPD exacerbations within the 12-month postindex period.](/cms/asset/0ad95e7d-69ae-4ba8-8b6e-5ec142714ca3/dcop_a_108967_f0003_c.jpg)
Figure 4 Factors associated with COPD-related health care costs within the 12-month postindex period.
Abbreviations: FEV1, forced expiratory volume in 1 second; PCP, primary care physician; ICS, inhaled corticosteroids; LABA, long-acting β-agonist; LAMA, long-acting muscarinic agent; SAMA, short-acting muscarinic antagonist; SABA, short-acting (inhaled) β2-adrenergic agonists; PDE4 inhibitors, phosphodiesterase-4 inhibitors.
![Figure 4 Factors associated with COPD-related health care costs within the 12-month postindex period.](/cms/asset/fcb3c9fe-bef9-4933-bfeb-63d2f215813a/dcop_a_108967_f0004_c.jpg)